Quarterly ResultApr 16, 2026, 09:01 AM
Oncotelic Reports FY2025 Net Income of $249M
AI Summary
Oncotelic Therapeutics, Inc. announced its financial results for the fiscal year ended December 31, 2025, reporting a significant net income after tax of approximately $249.0 million. This marks a substantial improvement from a net loss of approximately $4.8 million in the prior fiscal year. The positive financial performance was primarily attributed to a non-cash increase in the estimated fair value of the company's investment in its joint venture, GMP Biotechnology Limited.
Key Highlights
- Reported net income after tax of $249.0 million for FY 2025.
- This compares to a net loss of $4.8 million in FY 2024.
- Net income primarily driven by a non-cash increase in fair value of GMP Bio investment.